keyword
MENU ▼
Read by QxMD icon Read
search

Provenge

keyword
https://www.readbyqxmd.com/read/27076165/cancer-vaccines-a-brief-overview
#1
Sunil Thomas, George C Prendergast
Vaccine approaches for cancer differ from traditional vaccine approaches for infectious disease in tending to focus on clearing active disease rather than preventing disease. In this review, we provide a brief overview of different types of vaccines and adjuvants that have been investigated for the purpose of controlling cancer burdens in patients, some of which are approved for clinical use or in late-stage clinical trials, such as the personalized dendritic cell vaccine sipuleucel-T (Provenge) and the recombinant viral prostate cancer vaccine PSA-TRICOM (Prostvac-VF)...
2016: Methods in Molecular Biology
https://www.readbyqxmd.com/read/26834161/how-cancers-escape-immune-destruction-and-mechanisms-of-action-for-the-new-significantly-active-immune-therapies-helping-nonimmunologists-decipher-recent-advances
#2
REVIEW
Jonathan L Messerschmidt, George C Prendergast, Gerald L Messerschmidt
UNLABELLED: With the Food and Drug Administration and other worldwide regulatory authorities' approval of ipilimumab (Yervoy), sipuleucel-T (Provenge), nivolumab (Opdivo), and pembrolizumab (Keytruda), oncologic therapy has now moved into noncancer cell targets within the immune system. For many nonimmunologists, understanding how these vastly different therapies work to improve survival, like no other therapies have in the past, is a challenge. The present report reviews the normal function of the immune system, how cancers escape the normal immune system, and how these new therapies improve immune system reactions against cancers...
February 2016: Oncologist
https://www.readbyqxmd.com/read/26583636/navigating-treatment-of-metastatic-castration-resistant-prostate-cancer-nursing-perspectives
#3
Frank dela Rama, Caroline Pratz
BACKGROUND: Treatment of metastatic castration-resistant prostate cancer (mCRPC) has evolved rapidly. In particular, five new treatments that extend survival in mCRPC have been approved since 2010, including the chemotherapy cabazitaxel (Jevtana®), hormonal agents abiraterone (Zytiga®) and enzalutamide (Xtandi®), vaccine sipuleucel-T (Provenge®), and radiopharmaceutical radium-223 (Xofigo®); all have different indications and toxicity profiles. OBJECTIVES: This review discusses treatment advances in mCRPC, including considerations for side-effect management and treatment sequencing...
December 2015: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/26579225/a-quantitative-analysis-of-therapeutic-cancer-vaccines-in-phase-2-or-phase-3-trial
#4
REVIEW
Amabel Cl Tan, Anne Goubier, Holbrook E Kohrt
Despite the progress that has been made in other forms of cancer therapy, Provenge® (Sipuleucel-T) is the only FDA-approved vaccine for the treatment of cancer. To understand the current landscape of therapeutic oncology vaccines we performed a quantitative analysis of phase 2 and phase 3 therapeutic cancer vaccine trials. We highlight shifts in trends for the vaccine platforms examined, common adjuvant use, target indications, antibody or treatment combinations between past and recent trials as well as discuss the relationship between these trends and ratio between the number of phase 3: phase 2 for different vaccine platforms...
2015: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/26532688/sipuleucel-t-provenge%C3%A2-autopsy-of-an-innovative-change-of-paradigm-in-cancer-treatment
#5
S Jaroslawski, A Caban, M Toumi
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/26488270/prostate-cancer-immunotherapy-with-sipuleucel-t-current-standards-and-future-directions
#6
REVIEW
Xiao X Wei, Lawrence Fong, Eric J Small
The management of advanced prostate cancer, specifically metastatic castrate-resistant prostate cancer (mCRPC), remains a therapeutic challenge. Sipuleucel-T (Provenge; APC8015) was approved by the FDA in 2010 for the treatment of asymptomatic or minimally symptomatic mCRPC patients, and it remains the only FDA-approved immunotherapy for prostate cancer of any indication to date. Given the continued need to improve therapeutics in patients with advanced prostate cancer, as well as recent enthusiasm for cancer immunotherapy, there is a wide range of ongoing trials evaluating combinations of sipuleucel-T with other therapeutics...
2015: Expert Review of Vaccines
https://www.readbyqxmd.com/read/26403092/sipuleucel-t-provenge-%C3%A2-autopsy-of-an-innovative-paradigm-change-in-cancer-treatment-why-a-single-product-biotech-company-failed-to-capitalize-on-its-breakthrough-invention
#7
Szymon Jarosławski, Mondher Toumi
Approved by the US Food and Drug Administration (FDA) in 2010, sipuleucel-T (Provenge(®)) was the first 'personalized' cancer vaccine for the treatment of prostate cancer in a metastatic, non-symptomatic population of 30,000 men in the USA. Sipuleucel-T is prepared individually for each patient and infused in three sessions over a period of 1 month. However, in 2015, Dendreon, the owner of sipuleucel-T, filed for bankruptcy. This opinion paper reviews the probable reasons this innovative product failed to achieve commercial success...
October 2015: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/25977192/advances-in-strategies-and-methodologies-in-cancer-immunotherapy
#8
REVIEW
Samuel S K Lam, Feifan Zhou, Tomas Hode, Robert E Nordquist, Luciano Alleruzzo, Joseph Raker, Wei R Chen
Since the invention of Coley's toxin by William Coley in early 1900s, the path for cancer immunotherapy has been a convoluted one. Although still not considered standard of care, with the FDA approval of trastuzumab, Provenge and ipilimumab, the medical and scientific community has started to embrace the possibility that immunotherapy could be a new hope for cancer patients with otherwise untreatable metastatic diseases. This review aims to summarize the development of some major strategies in cancer immunotherapy, from the earliest peptide vaccine and transfer of tumor specific antibodies/T cells to the more recent dendritic cell (DC) vaccines, whole cell tumor vaccines, and checkpoint blockade therapy...
April 2015: Discovery Medicine
https://www.readbyqxmd.com/read/25941593/trial-watch-dendritic-cell-based-anticancer-therapy
#9
Norma Bloy, Jonathan Pol, Fernando Aranda, Alexander Eggermont, Isabelle Cremer, Wolf Hervé Fridman, Jitka Fučíková, Jérôme Galon, Eric Tartour, Radek Spisek, Madhav V Dhodapkar, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi
The use of patient-derived dendritic cells (DCs) as a means to elicit therapeutically relevant immune responses in cancer patients has been extensively investigated throughout the past decade. In this context, DCs are generally expanded, exposed to autologous tumor cell lysates or loaded with specific tumor-associated antigens (TAAs), and then reintroduced into patients, often in combination with one or more immunostimulatory agents. As an alternative, TAAs are targeted to DCs in vivo by means of monoclonal antibodies, carbohydrate moieties or viral vectors specific for DC receptors...
November 2014: Oncoimmunology
https://www.readbyqxmd.com/read/25800821/the-baculovirus-expression-vector-system-a-commercial-manufacturing-platform-for-viral-vaccines-and-gene-therapy-vectors
#10
REVIEW
Rachael S Felberbaum
The baculovirus expression vector system (BEVS) platform has become an established manufacturing platform for the production of viral vaccines and gene therapy vectors. Nine BEVS-derived products have been approved - four for human use (Cervarix(®), Provenge(®), Glybera(®) and Flublok(®)) and five for veterinary use (Porcilis(®) Pesti, BAYOVAC CSF E2(®), Circumvent(®) PCV, Ingelvac CircoFLEX(®) and Porcilis(®) PCV). The BEVS platform offers many advantages, including manufacturing speed, flexible product design, inherent safety and scalability...
May 2015: Biotechnology Journal
https://www.readbyqxmd.com/read/25518354/-current-status-and-prospects-of-immunotherapy-for-castration-resistant-prostate-cancer
#11
Junji Yatsuda, Masatoshi Eto
Surgery, radiation and chemotherapy are three major therapies for cancer. But now, hope is being gathered in immunotherapy as a treatment for fourth. Immunotherapy has been done than before, but they are non-specific immunotherapy. Those that have become hot topics are specific immunotherapies targeting certain molecules or antigens. In this chapter, current status and prospects of immunotherapy for castration-resistant prostate cancer (CRPC) are described. As concrete examples, Sipuleucel-T(Provenge), GVAX, PROSTVAC-VF, Ipilimumab (anti-CTLA-4 mAb), anti-PD-1 mAb and anti-PSMA mAb are cited...
December 2014: Nihon Rinsho. Japanese Journal of Clinical Medicine
https://www.readbyqxmd.com/read/25482400/regulation-of-cytotoxic-t-lymphocyte-trafficking-to-tumors-by-chemoattractants-implications-for-immunotherapy
#12
REVIEW
Rajesh K Sharma, Zinal S Chheda, Venkatakrishna R Jala, Bodduluri Haribabu
Cancer immunotherapy has recently emerged as an important treatment modality. FDA approval of provenge, ipilimumab and pembrolizumab has started to deliver on the long awaited promise of cancer immunotherapy. Many new modalities of immunotherapies targeting cytotoxic T lymphocytes (CTLs) responses, such as adoptive cell therapies and vaccines, are in advanced clinical trials. In all these immunotherapies, migration of CTLs to the tumor site is a critical step for achieving therapeutic efficacy. However, inefficient infiltration of activated CTLs into established tumors is increasingly being recognized as one of the major hurdles limiting efficacy...
April 2015: Expert Review of Vaccines
https://www.readbyqxmd.com/read/25318595/cancer-vaccine-adjuvants-recent-clinical-progress-and-future-perspectives
#13
REVIEW
Abid H Banday, Salika Jeelani, Victor J Hruby
Despite recent breakthroughs in the prognosis, prevention and treatment, cancer still remains the leading cause of death and affects millions of people worldwide. With the US FDA approval of various preventive cancer vaccines such as Gardasil (Merck), Cervarix (Glaxosmithkline) and the therapeutic vaccine Sipulencel-T (Provenge), cancer vaccine development is gaining huge ground. Approval of these vaccines has encouraged the concept of cancer treatment through cellular immunotherapy. The FDA approval of the above vaccines has provided support for renewed interest and attention which the development of new therapeutic cancer vaccines deserves...
February 2015: Immunopharmacology and Immunotoxicology
https://www.readbyqxmd.com/read/24762633/role-of-tertiary-lymphoid-structures-tls-in-anti-tumor-immunity-potential-tumor-induced-cytokines-chemokines-that-regulate-tls-formation-in-epithelial-derived-cancers
#14
Erica M Pimenta, Betsy J Barnes
Following the successes of monoclonal antibody immunotherapies (trastuzumab (Herceptin®) and rituximab (Rituxan®)) and the first approved cancer vaccine, Provenge® (sipuleucel-T), investigations into the immune system and how it can be modified by a tumor has become an exciting and promising new field of cancer research. Dozens of clinical trials for new antibodies, cancer and adjuvant vaccines, and autologous T and dendritic cell transfers are ongoing in hopes of identifying ways to re-awaken the immune system and force an anti-tumor response...
2014: Cancers
https://www.readbyqxmd.com/read/24619704/future-of-cancer-vaccines
#15
REVIEW
Hauke Winter, Bernard A Fox, Dominik Rüttinger
Extensive research in the area of active-specific immunotherapy has led to the approval of the first therapeutic cancer vaccine sipuleucel-T (Provenge™) in 2010. Even though a major milestone for the field of cancer immunotherapy, many obstacles towards successful integration of vaccination strategies into the oncologists' armamentarium remain. This chapter discusses possible future perspectives for cancer vaccines as a treatment modality in oncology with special focus on biomarkers (response prediction and patient selection), requirements for clinical trial design, and combination therapies (standard of care and new molecular entities)...
2014: Methods in Molecular Biology
https://www.readbyqxmd.com/read/24338683/novel-prostate-acid-phosphatase-based-peptide-vaccination-strategy-induces-antigen-specific-t-cell-responses-and-limits-tumour-growth-in-mice
#16
Jaimy M S Saif, Jayakumar Vadakekolathu, Shraddha S Rane, Danielle McDonald, Murrium Ahmad, Morgan Mathieu, A Graham Pockley, Lindy Durrant, Rachael Metheringham, Robert C Rees, Stephanie E B McArdle
Treatment options for patients with advanced prostate cancer remain limited and rarely curative. Prostatic acid phosphatase (PAP) is a prostate-specific protein overexpressed in 95% of prostate tumours. An FDA-approved vaccine for the treatment of advanced prostate disease, PROVENGE® (sipuleucel-T), has been shown to prolong survival, however the precise sequence of the PAP protein responsible for the outcome is unknown. As the PAP antigen is one of the very few prostate-specific antigens for which there is a rodent equivalent with high homology, preclinical studies using PAP have the potential to be directly relevant to clinical setting...
April 2014: European Journal of Immunology
https://www.readbyqxmd.com/read/24286020/trial-watch-dendritic-cell-based-interventions-for-cancer-therapy
#17
Erika Vacchelli, Ilio Vitale, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fučíková, Isabelle Cremer, Jérôme Galon, Eric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi
Dendritic cells (DCs) occupy a privileged position at the interface between innate and adaptive immunity, orchestrating a large panel of responses to both physiological and pathological cues. In particular, whereas the presentation of antigens by immature DCs generally results in the development of immunological tolerance, mature DCs are capable of priming robust, and hence therapeutically relevant, adaptive immune responses. In line with this notion, functional defects in the DC compartment have been shown to etiologically contribute to pathological conditions including (but perhaps not limited to) infectious diseases, allergic and autoimmune disorders, graft rejection and cancer...
October 1, 2013: Oncoimmunology
https://www.readbyqxmd.com/read/23896100/quality-of-life-after-sipuleucel-t-therapy-results-from-a-randomized-double-blind-study-in-patients-with-androgen-dependent-prostate-cancer
#18
RANDOMIZED CONTROLLED TRIAL
Tomasz M Beer, Paul F Schellhammer, John M Corman, L Michael Glodé, Simon J Hall, James B Whitmore, Mark W Frohlich, David F Penson
OBJECTIVE: To collect and analyze quality-of-life (QOL) data from PROvenge Treatment and Early Cancer Treatment trial (PROTECT, NCT00779402), a phase III, randomized controlled trial of sipuleucel-T in patients with asymptomatic androgen-dependent prostate cancer. METHODS: Patients experiencing prostate-specific antigen relapse after radical prostatectomy entered a 3- to 4-month run-in phase of androgen-deprivation therapy (ADT), followed by 2:1 randomization to sipuleucel-T or control...
August 2013: Urology
https://www.readbyqxmd.com/read/23678451/translational-approaches-towards-cancer-gene-therapy-hurdles-and-hopes
#19
Jaleh Barar, Yadollah Omidi
INTRODUCTION: Of the cancer gene therapy approaches, gene silencing, suicide/apoptosis inducing gene therapy, immunogene therapy and targeted gene therapy are deemed to sub-stantially control the biological consequences of genomic changes in cancerous cells. Thus, a large number of clinical trials have been conducted against various malignancies. In this review, we will discuss recent translational progresses of gene and cell therapy of cancer. METHODS: Essential information on gene therapy of cancer were reviewed and discussed towards their clinical translations...
2012: BioImpacts: BI
https://www.readbyqxmd.com/read/23454867/clinical-evaluation-of-therapeutic-cancer-vaccines
#20
Chizuru Ogi, Atsushi Aruga
Therapeutic cancer vaccines are an immunotherapy that targets tumor antigens to induce an active immune response. To date, Provenge® is the only therapeutic cancer vaccine approved by the United States Food and Drug Administration. Although therapeutic cancer vaccines have not been approved by the European Medicines Agency (EMA), they have been approved in several countries other than the United States (US) and the European Union (EU). Provenge® is the only approved cancer vaccine that showed significant primary endpoint efficacy in a phase III study at the time of approval...
May 2013: Human Vaccines & Immunotherapeutics
keyword
keyword
33631
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"